Skip to content
AnalystLens

Neurocrine Biosciences Annual Report (Amendment), Year Ended Dec 31, 1999

Filing Date
Filed November 30, 2000
Period End
December 31, 1999
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K/A filed November 30, 2000. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. filed Amendment No. 1 to its Form 10-K for the fiscal year ended December 31, 1999.

The company has not generated product revenues and expects none in the foreseeable future. Its 1999 revenues were $16.8 milliona, versus $16.0 million in 1998 and $26.1 million in 1997, and were driven by collaborations rather than product sales. Research and development expenses rose to $29.2 million and general and administrative expenses to $7.5 million, producing a net loss of $16.8 million, or $0.88 per share, compared with a net loss of $20.0 million, or $1.10 per share, in 1998.

The company's cumulative deficit was $41.7 millionb at December 31, 1999. Liquidity improved during 1999. Cash, cash equivalents and short-term investments totaled $91.1 million at year-end, up from $62.7 million a year earlier, after a December 1999 private placement of 2.3 million shares at $18.00 per share that produced net proceeds of $39.3 million.

Management believes existing capital resources, interest income and future collaboration payments will be sufficient for at least the next 12 months, but it expects operating losses over the next two to three years as clinical development grows. The company also states that it will need additional funding and may seek equity markets, strategic alliances or other financing. The filing highlights the Wyeth-Ayerst collaboration on excitatory amino acid transporters, which is valued at up to $81 millionc if a product is commercialized, and the Taisho option agreement for an altered peptide ligand for diabetes, which could be worth up to $45 million.

It also notes that Novartis terminated its multiple sclerosis agreement, returning worldwide rights to compound MSP771. The company expects to spend about $20 milliond in 2000 on clinical testing of its insomnia and brain cancer compounds, and it notes that the Year 2000 remediation program cost an estimated $175,000 with no material adverse effects reported.

Key Highlights

  1. 1999 total revenues of $16.8 million, compared with $16.0 million in 1998 and $26.1 million in 1997; the company has not generated product revenues to date.
  2. Net loss of $16.8 million, or $0.88 per share, in 1999, versus a net loss of $20.0 million, or $1.10 per share, in 1998.
  3. Research and development expenses increased to $29.2 million in 1999 from $21.8 million in 1998, and general and administrative expenses increased to $7.5 million from $6.6 million.
  4. Cash, cash equivalents and short-term investments of $91.1 million at December 31, 1999, up from $62.7 million, following a December 1999 private placement with net proceeds of $39.3 million.
  5. Management believes existing capital resources are sufficient for at least the next 12 months, and expects operating losses over the next two to three years.
  6. Wyeth-Ayerst collaboration (March 1999) valued at up to $81 million if a product is commercialized; Taisho option agreement for diabetes compound NBI-6024 could be valued at up to $45 million.
  7. Novartis terminated its Development and Commercialization Agreement effective January 7, 2000, and Neurocrine will reacquire worldwide rights to its multiple sclerosis compound, MSP771.

Frequently Asked Questions

  1. Does Neurocrine Biosciences generate revenue from product sales?

    No. The company states that it has not generated any revenues from the sale of products and does not expect to generate product revenues in the foreseeable future. Its 1999 revenues came from sponsored research and development funding, milestone achievements and other collaboration-related income, totaling $16.8 million.

  2. How much did the company lose in 1999, and how has that changed?

    The company reported a net loss of $16.8 million, or $0.88 per share, for 1999, compared with a net loss of $20.0 million, or $1.10 per share, for 1998. The 1998 loss included a $4.9 million write-off of acquired in-process research and development. Management expects similar operating losses over the next two to three years.

  3. Is the company well funded?

    At December 31, 1999, cash, cash equivalents and short-term investments totaled $91.1 million. Management believes these resources, together with interest income and future collaboration payments, will be sufficient for at least the next 12 months. The company also states it will require additional funding for its programs and may seek equity markets, strategic alliances or other financing, and that it cannot assure such funding will be available on acceptable terms.

  4. What are the company's main development programs and their expected costs?

    The insomnia and brain cancer compounds are in early clinical testing, and the company expects to spend approximately $20 million on their clinical testing during 2000. It estimates that each compound could cost an additional $50 to $150 million and take up to five years to reach commercial viability if it is not collaborated. The company also expects its gross research costs on the melanocortin receptor and excitatory amino acid transporter programs to approximate $5 million in fiscal 2000.

  5. What collaborations could provide future revenue?

    The Wyeth-Ayerst agreement on excitatory amino acid transporters, entered in March 1999, could be valued at up to $81 million if a product is commercialized and includes research funding, milestones and royalties. The Taisho agreement gives Taisho an option on European and Asian rights to the diabetes compound NBI-6024 and could be valued at up to $45 million. The Janssen amendment provides $5.0 million in sponsored research funding and up to $3.5 million in milestones. The filing notes that $3.0 million in Wyeth-Ayerst milestone payments received in 1999 may be subject to SAB 101.